[1] Taylor JW, Stein MN, Murphy MJ,et al. Cholestatic liver dysfunction after long-term phenytoin therapy. Arch Neurol, 1984, 41: 500-501.
[2] Velasco MJ, McDermott J.Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome and hepatitis induced by phenytoin.Int J Dermatol, 2014, 53: 490-493.
[3] Mullick FG, Ishak KG. Hepatic injury associated with diphenyl-hydantoin therapy. A clinicopathologic study of 20 cases. Am J Clin Pathol, 1980, 74: 442-452.
[4] Altunta Y, Oztürk B, Erdem L, et al. Phenytoin-induced toxic cholestatic hepatitis in a patient with skin lesions:case report.South Med J, 2003, 96: 201-203.
[5] Sawsan AF, Nihad A, Sally AE,et al.Phenytoin-induced acute liver injury case report: possible drug interactions and risk factors.Ain-Shams J Anesthesiol, 2013, 6:329-331.
[6] Pillai LV, Vaidya N, Khade AD,et al. Variability of serum phenytoin level in critically ill head injured patients in ICU. Indian J Crit Care Med, 2008, 12: 24-27.
[7] Roy AK, Mahoney HC, Levine RA. Phenytoin-induced chronic hepatitis. Dig Dis Sci, 1993, 38: 740-743.
[8] Munns AJ, De Voss JJ, Hooper WD,et al.Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol, 1997, 10: 1049-1058.
[9] Cuttle L, Munns AJ, Hogg NA,et al.Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos, 2000, 28: 945-950.
[10] Roy D, Snodgrass WR. Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes. J Pharmacol Exp Ther, 1990, 252: 895-900.
[11] Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 2002, 418: 191-195.
[12] Huang H, Tohme S, Al-Khafaji AB,et al.Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology, 2015, 62: 600-614.
[13] Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis, 2010, 28: 31-44.
[14] Winn LM, Wells PG.Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol Pharmacol, 1995, 48: 112-120.
[15] Winn LM, Wells PG. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic Biol Med, 1999, 26: 266-274.
[16] Brackett CC, Bloch JD. Phenytoin as a possible cause of acetaminophen hepatotoxicity: case report and review of the literature. Pharmacotherapy, 2000, 20: 229-233. |
